subject area of
- Adaptation following intestinal resection: mechanisms and signals Journal Articles
- Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis Journal Articles
-
Design and baseline characteristics of participants in the
R esearching cardiovascularE vents with aW eeklyIN cretin inD iabetes (REWIND ) trial on the cardiovascular effects of dulaglutide Journal Articles - Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis Journal Articles
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Journal Articles
-
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the
REWIND randomized trial Journal Articles - Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Journal Articles
- Dulaglutide slows kidney disease in type 2 diabetes − Author's reply Journal Articles
- Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial Journal Articles
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus Journal Articles
- Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial Journal Articles
-
Efficacy and safety outcomes of dulaglutide by baseline
HbA1c : A post hoc analysis of theREWIND trial Journal Articles - Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial Journal Articles
- Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND Journal Articles
- Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States Journal Articles
- Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics Journal Articles
- Glucagon-like peptide-2-enhanced barrier function reduces pathophysiology in a model of food allergy Journal Articles
- HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial Journal Articles
- In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y. Journal Articles
- Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin Journal Articles
- The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial Journal Articles
- Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis Journal Articles